放化疗联合治疗食管癌患者的临床疗效及预后分析

目的探讨并分析同步放化疗联合治疗食管癌患者的疗效和预后。方法选取2009年3月至2011年3月收治的78例晚期食管癌患者,按照治疗方式分为观察组和对照组,每组39例。对照组患者给予序贯放化疗治疗,观察组患者给予同步放化疗治疗。比较两组患者的近期疗效,并对患者预后进行分析。结果观察组患者治疗总有效率为74.4%（29/39）,对照组患者为51.3%（20/39）,观察组总有效率高于对照组（P〈0.05）。观察组患者白细胞减少和放射性食管炎发生率分别为64.1%和74.4%,高于对照组（P〈0.05）。两组患者的1年生存率差异无统计学意义（P〉0.05）,而观察组的2年生存率显著高于对照组（P〈0.05）。观察组复发率和转移率均低于对照组（P〈0.05）。结论同步放化疗显著提高了患者的治疗效果和2年生存率,抑制了肿瘤的转移和复发,且无严重不良反应出现,有助于患者完成治疗。

Analysis on efficacy and prognosis of patients with esophageal carcinoma treated by concurrent radiochemotherapy

Objective Analysis on efficacy and prognosis of patients with esophageal cancer treated by concurrent radiochemotherapy. Methods 78 patients were divided into observation group and control group according to the treatment. The control group received sequential radiotherapy and chemotherapy, and the observation group were treated by concurrent radiochemotherapy. The short-term efficacy and prognosis of the two groups was compared. Results The overall response rate of observation group and control group were 74.4% （29/39） and 51.3% （20/39） respectively. The overall response rate of observation group was higher than that of the control group （ P 〈 0. 05 ）. The incidence of neutropenia and radiation esophagi- tis in observation group were 64. 1% and 74. 4%, respectively, which were higher than those of the control group （P 〈0.05）. There was no significant difference in one year survival rate between the two groups （P 〉 O. 05 ）. However, the two-year survival rate of the observation group was significantly higher （ P 〈 0. 05） than that of control group. Relapse rate and metastasis rate of the observation group were lower than those of the control group （P 〈 0. 05）. Conclusion Concurrent radiochemotherapy significantly improved patients＇ outcomes and two-year survival rate, inhibited tumor metastasis and recurrence, showed no serious adverse reactions, and helped patients complete treatment.